Please ensure Javascript is enabled for purposes of website accessibility

Wall Street’s Best Digest Top Picks Daily Alert

Despite weak analyst sentiment, this biotech is looking healthy for the new year.

Despite weak analyst sentiment, this biotech is looking healthy for the new year.

Anavex Life Sciences Corp. (AVXL)
From The National Investor

I first recommended biotech researcher Anavex Life Sciences Corp. (AVXL) at the beginning of 2015. A combination of good news, an up listing to the full Nasdaq and a lot of excited press sent AVXL skyward in fairly short order; from under $1.00 to a bit over $14.00/share at the peak.

In the two-plus years since that peak, however, the company became the subject of brickbats among a few biotech-oriented bloggers. Whether too slow in clinical trials progress or whatever, sentiment has been sour on the company. Incredibly, it still is; and this despite its extremely encouraging quarterly report on December 11.

I was newly impressed on the call by the company’s C.E.O. and President Dr. Christopher Missling’s summation of things: “We are entering fiscal 2018 with our strongest balance sheet to date, which allows the company to carry out planned clinical studies for ANAVEX®2-73. This year has been an extraordinarily productive period for Anavex, with advanced preparation underway for studies in Rett syndrome, Alzheimer’s disease and Parkinson’s disease – all indications with high unmet need. . .”

While I can’t promise the explosive gains our Members enjoyed in 2015, Anavex—bouncing bouncing around the $3.25/share level—is newly compelling; and I just added it back to my recommendations as a BUY.

Chris Temple, The National Investor,, 224-308-2587, January 4, 2017